ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).
Enriqueta Felip, Sergey Orlov, Keunchil Park et al. · Journal of Clinical Oncology · 2015
8060 Background: Ceritinib demonstrated clinical activity in ALKi-pretreated and -naïve pts with ALK+ NSCLC, including those with brain metastases (BM; pivotal ASCEND-1 study). ASCEND-3 (NCT01685138) evaluated efficacy and safety of ceritinib in ALKi-naïve pts. Methods: At 27June 2014 data cutoff, 124 pts enrolled worldwide received oral ceritinib 750 mg/d. Whole body (WB) and intracranial (I) responses were assessed by investigator. Prior chemotherapy (≤3 lines) was permitted. Results: Median age of enrolled pts was 56 (27–82); 40.3% were male, 59.7% Asian and 38.7% Caucasian; 40.3% had BM, of which 46% had no prior brain radiation (BRT). Median time from initial diagnosis to treatment start was 13.5 (1.0–283.1) mos; median exposure duration was 8.0 (0.1–16.2) mos; median follow-up (range) was 8.3 (0.6-16.3) mos. Investigator-assessed efficacy outcomes are located in the table below. At baseline 10 pts had investigator-assessed measurable brain lesions (MBL); IDCR was 80.0% (95% CI: 44.4, 97.5); in 6 pts with MBL and no prior BRT, all responses in brain (2 PR) matched or exceeded WB response. Most common AEs (mostly Grade 1/2) were gastrointestinal: diarrhea (82.3%), nausea (74.2%), and vomiting (66.9%); 7.3% pts discontinued due to AEs, with no one AE predominating. Conclusions: Ceritinib achieved robust ORR and promising DOR/PFS in pts with and without baseline BM. Ceritinib showed brain responses even in pts with no prior BRT. Safety outcomes were similar to the ASCEND-1 trial. Clinical trial information: NCT01685138. BM N=50 No BM N=74 All N=124 WB ORR (CR+PR), n (%) [95% CI] 29 (58.0) [43.2, 71.8] 50 (67.6) [55.7, 78.0] 79 (63.7) [54.6, 72.2] WB DCR (CR+PR+SD), n (%) [95% CI] 43 (86.0) [73.3,94.2] 68 (91.9) [83.2,97.0] 111 (89.5) [82.7, 94.3] Median Duration of Response (DOR), Mos [95% CI] 9.1 [7.5, NE] 10.8 [9.3, 10.8] 9.3 [9.1, NE] Median Progression Free Survival (PFS)* Mos [95% CI] 10.8 [7.3, NE] 11.1 [9.2, 12.8] 11.1 [9.3, NE] NE = Not Estimable *Follow-up ongoing: 84 (67.7%) pts censored; 77 (62.1%) ongoing without event.
Cited by 77 works. doi:10.1200/jco.2015.33.15_suppl.8060